Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | CCR3 | P51677 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23594252 | 0.89 | ACHE (0.35) | ACHECHRM5ADRA2CHRH1CCR3 | |
| SCHEMBL4106076 | 0.88 | GRIN2D (0.32) | OPRM1 | |
| SCHEMBL25852133 | 0.87 | ACHE (0.36) | ACHECHRM5ADRA2C | |
| SCHEMBL24453218 | 0.87 | ACHE (0.40) | ACHECHRM5ADRA2C | |
| SCHEMBL118241 | 0.86 | CHRM5 (0.41) | ACHECHRM5ADRA2C | |
| SCHEMBL11916111 | 0.84 | CHRM5 (0.50) | ACHECHRM5ADRA2COPRM1OPRL1 | |
| SCHEMBL2629515 | 0.84 | CHRM5 (0.56) | ACHECHRM5ADRA2C | |
| SCHEMBL23594124 | 0.84 | ACHE (0.38) | ACHECHRM5ADRA2COPRM1OPRL1 | |
| SCHEMBL10191387 | 0.83 | ACHE (0.50) | ACHECHRM5ADRA2C | |
| SCHEMBL21933163 | 0.83 | ACHE (0.40) | ACHECHRM5ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | ACHE 3972/4885CHRM5 4858/4885ADRA2C 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.